Coronary Artery Disease (CAD) hospitalizes more than 160,000 Canadians every year, and almost one quarter of those patients die from this common form of heart disease. But now a team of Vancouver based researchers has identified a key predictor of mortality in CAD patients, which means that specialists can better determine how to treat and improve outcomes for patients with CAD.
In an art. . .
Dr. David Granville, Associate professor, UBC and founder and CSO, viDA Therapeutics Inc; has been named one of Vancouver's Top 40 under 40 for 2009 by Business in Vancouver (www.biv.com).
To read more about Dr. David Granville and why he is one of Vancouver's Top 40 under 40 visit: Read the full story